{"schema_version":"secwatch.filing_event.v1","accession":"0001698530-25-000006","form_type":"8-K/A","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.484666+00:00","generated_at":"2026-05-27T14:44:44.634012+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exicure acquires GPCR Therapeutics USA and signs license/collaboration agreement","bullets":["Acquired all outstanding equity of GPCR Therapeutics USA from GPCR Therapeutics Inc.; deal closed concurrently with execution.","Entered License and Collaboration Agreement to develop and commercialize GPCR's technologies and patents.","Must make milestone payments tied to clinical trial, regulatory, and sales milestones; royalty of at least 10% of net sales.","Corrected press release filed as an amendment to the January 22, 2025 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-25-000006","json":"https://secwatch.observer/filing/0001698530-25-000006.json","markdown":"https://secwatch.observer/filing/0001698530-25-000006.md","text":"https://secwatch.observer/filing/0001698530-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853025000006/0001698530-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853025000006/xcur-20250123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T14:44:44.634012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}